WO2006020837A3 - Method of detecting thyroid cancer - Google Patents

Method of detecting thyroid cancer Download PDF

Info

Publication number
WO2006020837A3
WO2006020837A3 PCT/US2005/028688 US2005028688W WO2006020837A3 WO 2006020837 A3 WO2006020837 A3 WO 2006020837A3 US 2005028688 W US2005028688 W US 2005028688W WO 2006020837 A3 WO2006020837 A3 WO 2006020837A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid cancer
detecting thyroid
mrna
nucleic acid
detecting
Prior art date
Application number
PCT/US2005/028688
Other languages
French (fr)
Other versions
WO2006020837A2 (en
Inventor
Manjula Gupta
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Priority to JP2007525816A priority Critical patent/JP2008509672A/en
Priority to AU2005272696A priority patent/AU2005272696A1/en
Priority to CA002576912A priority patent/CA2576912A1/en
Priority to BRPI0514265-2A priority patent/BRPI0514265A/en
Priority to EP05786259A priority patent/EP1778872A2/en
Publication of WO2006020837A2 publication Critical patent/WO2006020837A2/en
Publication of WO2006020837A3 publication Critical patent/WO2006020837A3/en
Priority to AU2009210417A priority patent/AU2009210417A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of detecting thyroid cancer in a subject includes obtaining a nucleic acid sample from a bodily sample of the subject and determining whether the nucleic acid sample contains at least one of thyroid stimulating hormone receptor (TSHR) mRNA or thyroglobulin (Tg) mRNA.
PCT/US2005/028688 2004-08-11 2005-08-11 Method of detecting thyroid cancer WO2006020837A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007525816A JP2008509672A (en) 2004-08-11 2005-08-11 Method for detecting thyroid cancer
AU2005272696A AU2005272696A1 (en) 2004-08-11 2005-08-11 Method of detecting thyroid cancer
CA002576912A CA2576912A1 (en) 2004-08-11 2005-08-11 Method of detecting thyroid cancer
BRPI0514265-2A BRPI0514265A (en) 2004-08-11 2005-08-11 method for detecting thyroid cancer in a patient; and, preoperative assay to determine if thyroid cancer in a patient is benign or malignant.
EP05786259A EP1778872A2 (en) 2004-08-11 2005-08-11 Method of detecting thyroid cancer
AU2009210417A AU2009210417A1 (en) 2004-08-11 2009-08-21 Method of detecting thyroid cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60058904P 2004-08-11 2004-08-11
US60/600,589 2004-08-11

Publications (2)

Publication Number Publication Date
WO2006020837A2 WO2006020837A2 (en) 2006-02-23
WO2006020837A3 true WO2006020837A3 (en) 2006-09-28

Family

ID=35908168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028688 WO2006020837A2 (en) 2004-08-11 2005-08-11 Method of detecting thyroid cancer

Country Status (8)

Country Link
US (1) US20070065833A1 (en)
EP (1) EP1778872A2 (en)
JP (1) JP2008509672A (en)
KR (1) KR20070044048A (en)
AU (2) AU2005272696A1 (en)
BR (1) BRPI0514265A (en)
CA (1) CA2576912A1 (en)
WO (1) WO2006020837A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US8394580B2 (en) * 2007-08-17 2013-03-12 The Johns Hopkins University Protein markers for the detection of thyroid cancer metastasis
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
JP6257125B2 (en) 2008-11-17 2018-01-10 ベラサイト インコーポレイテッド Molecular profiling methods and compositions for disease diagnosis
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
JP6078339B2 (en) * 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド Methods and compositions for diagnosis of thyroid status
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CN106498076A (en) 2010-05-11 2017-03-15 威拉赛特公司 For diagnosing the method and composition of symptom
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (en) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res PROSTATE CANCER PROGNOSIS USING BIOMARKERS
CN105378104A (en) 2013-03-15 2016-03-02 威拉赛特公司 Methods and compositions for classification of samples
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
JP7356788B2 (en) 2014-11-05 2023-10-05 ベラサイト インコーポレイテッド Systems and methods for diagnosing idiopathic pulmonary fibrosis in transbronchial biopsies using machine learning and high-dimensional transcriptional data
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
WO2017167217A1 (en) 2016-04-01 2017-10-05 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN110506127B (en) 2016-08-24 2024-01-12 维拉科特Sd公司 Use of genomic tags to predict responsiveness of prostate cancer patients to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
CN108089011A (en) * 2018-01-09 2018-05-29 广州市康润生物科技有限公司 A kind of new application of tachysynthesis detecting system in operation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056953A1 (en) * 1997-06-10 1998-12-17 Johns Hopkins University School Of Medicine Methods for thyroid cell detection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391579B1 (en) * 1996-02-01 2002-05-21 Albert Einstein College Of Medicine Of Yeshiva University Thyroid sodium/iodide symporter and nucleic acid encoding same
US6066449A (en) * 1997-04-15 2000-05-23 The Trustees Of Columbia University In The City Of New York Method of detecting metastatic thyroid cancer
US20020009778A1 (en) * 1998-05-29 2002-01-24 Incyte Pharmaceuticals, Inc. Thyroid and pituitary membrane protein
US6436642B1 (en) * 1999-04-20 2002-08-20 Curagen Corporation Method of classifying a thyroid carcinoma using differential gene expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056953A1 (en) * 1997-06-10 1998-12-17 Johns Hopkins University School Of Medicine Methods for thyroid cell detection

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARTURI FRANCO ET AL: "Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 82, no. 5, 1997, pages 1638 - 1641, XP002376297, ISSN: 0021-972X *
BARZON LUISA ET AL: "Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse", INTERNATIONAL JOURNAL OF CANCER, vol. 110, no. 6, 20 July 2004 (2004-07-20), pages 914 - 920, XP009065001, ISSN: 0020-7136 *
CHINNAPPA PRIYA ET AL: "Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: Sensitive and specific markers for thyroid cancer", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 89, no. 8, August 2004 (2004-08-01), pages 3705 - 3709, XP002376299, ISSN: 0021-972X *
GRASSO YING Z ET AL: "Specificity of peripheral blood RT-PCR for thyroglobulin and TSH-receptor in detecting thyroid cancer cells: The importance of primer selection", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 392, XP001246818, ISSN: 0197-016X *
MUSHOLT P B ET AL: "Detection of circulating thyrocytes in the postoperative care of patients with differentiated thyroid carcinoma: Significance of ectopic transcription of thyroglobulin and TSH receptor in peripheral blood cells", LANGENBECK'S ARCHIVES OF SURGERY, vol. 385, no. 8, December 2000 (2000-12-01), & JOINT SURGICAL RESEARCH MEETING; LUEBECK, GERMANY; NOVEMBER 09-11, 2000, pages 544, XP002376298, ISSN: 1435-2443 *
WAGNER KRISTIN ET AL: "Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: Diagnostic synergy for detecting thyroid cancer", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 90, no. 4, April 2005 (2005-04-01), pages 1921 - 1924, XP002376300, ISSN: 0021-972X *

Also Published As

Publication number Publication date
EP1778872A2 (en) 2007-05-02
AU2009210417A1 (en) 2009-09-10
WO2006020837A2 (en) 2006-02-23
BRPI0514265A (en) 2008-06-10
CA2576912A1 (en) 2006-02-23
US20070065833A1 (en) 2007-03-22
JP2008509672A (en) 2008-04-03
KR20070044048A (en) 2007-04-26
AU2005272696A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2006020837A3 (en) Method of detecting thyroid cancer
WO2005113817A3 (en) Aptamer-nanoparticle conjugates and method of use for target analyte detection
HK1199498A1 (en) Voltammetric systems for assaying biological analytes
WO2004055519A3 (en) Specific markers for pancreatic cancer
WO2006026601A3 (en) Homogeneous enzyme immunoassay for oral fluid
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO1999041584A3 (en) METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY hCG ASSAY
EP1771546A4 (en) Electronic analyte assaying device
WO2006089027A3 (en) Lateral flow test kit and method for detecting an analyte
WO2008039944A3 (en) Method and apparatus for providing analyte sensor insertion
WO2002035232A3 (en) Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
WO2008083984A8 (en) A navigation device and method for improving a time to identify a location of the navigation device
WO2006066965A3 (en) Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer
WO2006069373A8 (en) Diagnosis of preeclampsia
WO2005092038A3 (en) Methods for the detection of nucleic acid differences
GB2436774B (en) Electrically active combinatorial-chemical (EACC) chip for biochemical analyte detection
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
IL146454A0 (en) METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY hCG ASSAY
WO2005106036A3 (en) Methods and compositions for assaying analytes
WO2002037112A3 (en) Detection of ovarian cancer
WO2006047591A3 (en) Rapid microfluidic assay for analyte interactions
WO2008060651A3 (en) Sparc and methods of use thereof
WO2005113797A3 (en) METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
WO2005078624A3 (en) A method of recruiting patients for a clinical study
EP1557662A4 (en) Determination method for automatically identifying analyte liquid and standard solution for biosensor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2007525816

Country of ref document: JP

Ref document number: 2005272696

Country of ref document: AU

Ref document number: 2576912

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005786259

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005272696

Country of ref document: AU

Date of ref document: 20050811

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005272696

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077005647

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005786259

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514265

Country of ref document: BR